Korea Pharma
Key metrics
Earnings
| Revenue, Q3 2026 | ₩26.5bn |
|---|---|
| Revenue QoQ | +2.1% |
| Revenue YoY | +10.2% |
| Operating income, Q3 2026 | ₩3.2bn |
| Operating income QoQ | +47.3% |
| Operating income YoY | +528.7% |
Share buybacks
| Buyback decided, last 3 months | ₩1.0bn |
|---|---|
| Buyback decided, last 3 months, % of shares | Not available |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | Not available |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | Not available |
| Buyback decided, last 12 months | ₩1.0bn |
| Buyback decided, last 12 months, % of shares | Not available |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | Not available |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | Not available |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩15.0bn |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 1,391,207 shares |
| Potential new shares, % of shares | Not available |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 1 |
|---|---|
| DART filings, previous 3 months | 4 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
No insider transactions in the last 12 months.
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩87.6bn | -₩887m |
| 2024 | ₩81.3bn | ₩6.1bn |
| 2023 | ₩83.2bn | ₩6.3bn |
Filing timeline
-
Korea Pharma ₩1.0bn share buyback via trust contract with broker
Korea Pharma filed a share buyback arranged through a trust contract with NH Investment & Securities, with a contract amount of ₩1.0bn. The contract runs from Oct 6, 2026 to Apr 6, 2027, and the stated purpose is enhancing shareholder value and paying employee stock options. By our calculation, the amount equals 1.1% of FY2025 revenue (₩87.6bn).